DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Indoco Remedies Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·7 Oct 2026, 8:45 am

Indoco Remedies

Indoco Remedies Limited has informed the stock exchanges that it has received a certificate under SEBI's Depositories and Participants Regulations, 2018. This regulatory filing confirms that the company has complied with the necessary requirements for its securities to be held in electronic form.

For investors, this development is largely procedural and serves as a standard compliance check. It ensures that the company's shares are eligible for electronic settlement and trading, maintaining the integrity of the market infrastructure. While this news does not alter the company's operational outlook, it reinforces the company's adherence to regulatory norms.

Investors should monitor the company's future quarterly results and operational updates to gauge its performance. This filing is a routine administrative step and should not be viewed as a trigger for immediate market action.